[{"data":1,"prerenderedAt":184},["ShallowReactive",2],{"media-slots-en":3,"guide-item-en-hematopoietic-stem-cell-transplant-basic-knowledge":61},{"about.hero":4,"about.video":6,"about.video-cover":8,"charity.hero":10,"contact.hero":12,"evidence.hero":14,"footer.qr-blood":16,"footer.qr-mini":18,"footer.qr-official":20,"footer.qr-solid":22,"guide.hero":24,"home.hero":26,"home.news-featured":28,"home.story-featured":30,"news.hero":32,"news.lead":34,"news.thumb":36,"stories.cover":41,"stories.hero":48,"stories.lead":50,"wiki.cat":52,"wiki.detail-hero":57,"wiki.hero":59},[5],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fpc_banner\u002F%E5%85%B3%E4%BA%8E%E5%8D%9A%E5%8C%BB%E5%90%8C%E8%A1%8C_en.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[7],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fabout\u002F%E9%A3%9E%E4%B9%A620260729-233252_compressed.mp4",[9],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fabout\u002F%E9%A3%9E%E4%B9%A620260729-233252_frame1.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[11],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fpc_banner\u002F%E5%85%AC%E7%9B%8A%E8%B5%84%E6%BA%90%E9%93%BE%E6%8E%A5_en.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[13],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F08\u002Fbde8f2354d29ffca7dcfe395ef4711b2.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[15],"https:\u002F\u002Fwww.yyhmedical.com\u002Fimages\u002Fevidence\u002Fhero.jpg",[17],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fabout\u002Fqr-blood.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[19],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fabout\u002Fqr-mini.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[21],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fabout\u002Fqr-official.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[23],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fabout\u002Fqr-solid.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[25],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fpc_banner\u002F%E7%96%BE%E7%97%85%E7%9F%A5%E8%AF%86%E5%BA%93_en.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[27],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fpc_banner\u002F%E9%A6%96%E9%A1%B5_en.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[29],"\u002Fimages\u002Fhome\u002Fnews-featured.jpg",[31],"\u002Fimages\u002Fhome\u002Fstory-featured.jpg",[33],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fpc_banner\u002F%E6%82%A3%E5%8F%8B%E5%85%B3%E6%B3%A8_en.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[35],"\u002Fimages\u002Fnews\u002Flead.jpg",[37,38,39,40],"\u002Fimages\u002Fnews\u002Fn1.jpg","\u002Fimages\u002Fnews\u002Fn2.jpg","\u002Fimages\u002Fnews\u002Fn3.jpg","\u002Fimages\u002Fnews\u002Fn4.jpg",[42,43,44,45,46,47],"\u002Fimages\u002Fstories\u002Fs1.jpg","\u002Fimages\u002Fstories\u002Fs2.jpg","\u002Fimages\u002Fstories\u002Fs3.jpg","\u002Fimages\u002Fstories\u002Fs4.jpg","\u002Fimages\u002Fstories\u002Fs5.jpg","\u002Fimages\u002Fstories\u002Fs6.jpg",[49],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fpc_banner\u002F%E6%82%A3%E8%80%85%E6%95%85%E4%BA%8B_en.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",[51],"\u002Fimages\u002Fstories\u002Flead.jpg",[53,54,55,56],"\u002Fimages\u002Fwiki\u002Fcat-1.jpg","\u002Fimages\u002Fwiki\u002Fcat-2.jpg","\u002Fimages\u002Fwiki\u002Fcat-3.jpg","\u002Fimages\u002Fwiki\u002Fcat-4.jpg",[58],"\u002Fimages\u002Fwiki\u002Fdetail-hero.jpg",[60],"https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fstatic\u002Fpc_banner\u002F%E6%8A%97%E7%99%8C%E7%99%BE%E7%A7%91_en.jpg?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",{"slug":62,"kind":63,"title":64,"summary":65,"cover":66,"faqCount":67,"contentHtml":68,"toc":69,"relatedQuestions":179,"ymyl":180,"hasAlternate":183,"updatedAt":88},"hematopoietic-stem-cell-transplant-basic-knowledge","manual","Hematopoietic Stem Cell Transplantation: The Basics","Learn what hematopoietic stem cell transplantation (HSCT) is, how it rebuilds blood and immune function, and which patients may need it.","https:\u002F\u002Fgaobo-byh-h5.oss-cn-beijing.aliyuncs.com\u002Fbytx-pc-uploads\u002F2026\u002F09\u002Fead57a0b975951df93713e0f2a87934c.png?x-oss-process=image\u002Fresize,limit_1,w_1600\u002Fquality,q_80\u002Fformat,webp",6,"",[70,89,107,125,143,161],{"key":71,"title":72,"html":73,"relatedQuestions":74,"hotSummary":87,"updatedAt":88},"what-is-hematopoietic-stem-cell-transplantation","What Is Hematopoietic Stem Cell Transplantation (HSCT), and How Can It Treat Blood Diseases?","\u003Cp>\u003Cspan style=\"color: rgb(15, 17, 21); background-color: rgb(255, 255, 255); font-size: 15px;\">Overview: Hematopoietic stem cell transplantation (HSCT) is a treatment approach that helps patients rebuild normal hematopoiesis and immune function by infusing healthy hematopoietic stem cells. It is mainly used to treat certain hematologic malignancies, hematopoietic failure disorders, and some genetic diseases and immunodeficiency disorders. Depending on the patient’s disease type, risk level, and physical condition, doctors will choose different treatment options, such as autologous hematopoietic stem cell transplantation or allogeneic hematopoietic stem cell transplantation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr\u002F>\u003C\u002Fp>\u003Cp>\u003Cbr\u002F>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Hematopoietic stem cell transplantation (HSCT) is a treatment that gives healthy blood-forming stem cells through a vein. These cells travel to the bone marrow, begin to grow, and help rebuild normal blood production and immune function.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">When patients and families first hear the term “stem cell transplant,” they may wonder whether it means replacing the bone marrow. HSCT is not simply a bone marrow replacement. It uses healthy stem cells to help the body build a new blood-forming system.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Hematopoietic stem cells can continuously produce red blood cells, which carry oxygen; white blood cells, which help fight infection; and platelets, which help stop bleeding and form blood clots.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">When a disease damages the bone marrow or causes abnormal cells, such as leukemia cells, to grow out of control, the body may not make enough healthy blood cells. This can lead to anemia, a higher risk of infection, and bleeding. HSCT aims to restore healthy blood production with new stem cells.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong style=\"color: rgb(79, 129, 189);\">\u003Cspan style=\"font-size: 15px; color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Why can HSCT treat blood diseases?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">HSCT can treat some blood diseases in two main ways.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">1. Rebuilding the blood-forming system. Hematopoietic stem cells can renew themselves and develop into different blood cells. After they enter the body, healthy stem cells can engraft in the bone marrow and begin producing new blood cells. This may help rebuild blood production in people whose bone marrow has been seriously damaged, including some patients with leukemia or aplastic anemia.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">2. Providing an immune effect against cancer. In an allogeneic HSCT, immune cells from the donor may recognize and attack some cancer cells that remain in the patient’s body. This is called the graft-versus-leukemia (GVL) effect. It is one of the important ways that allogeneic HSCT can treat certain blood cancers.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cbr\u002F>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>What is the difference between HSCT and a bone marrow transplant?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">People often use “bone marrow transplant” to mean HSCT, but the terms are not exactly the same. In the past, most blood-forming stem cells were collected from bone marrow, so “bone marrow transplant” became the common name.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Today, stem cells may come from bone marrow, peripheral blood, or cord blood. Peripheral blood is now widely used and can be collected with an established blood-cell separation process. Cord blood also contains hematopoietic stem cells and may be used for some patients. For this reason, “hematopoietic stem cell transplantation” is the more accurate medical term\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong style=\"color: rgb(79, 129, 189);\">\u003Cspan style=\"font-size: 15px; color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>What are the main types of HSCT?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">The two main types are autologous HSCT and allogeneic HSCT.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Autologous HSCT uses the patient’s own stem cells. The cells are collected and stored before high-dose treatment, then returned to the patient to help blood production recover. This approach is commonly used for some lymphomas, multiple myeloma, and selected other blood diseases.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Allogeneic HSCT uses stem cells from a healthy donor. The donor may be a fully matched sibling, an unrelated donor, or a haploidentical family member. In addition to rebuilding blood production, donor immune cells may provide an anti-cancer effect. Allogeneic HSCT is therefore an important treatment option for some patients with high-risk blood cancers.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong style=\"color: rgb(79, 129, 189);\">\u003Cspan style=\"font-size: 15px; color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Who may need HSCT?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">HSCT is not needed for every person with a blood disease. The transplant team considers the type of disease, risk group, chromosome and gene test results, response to treatment, age, and overall health.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Some patients with high-risk acute leukemia, relapsed or treatment-resistant blood cancers, or high-risk myelodysplastic syndromes (MDS) may be considered for HSCT when medicines alone are unlikely to provide long-term control.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">HSCT may also be considered for severe bone marrow failure, such as severe aplastic anemia, and for selected inherited blood disorders or congenital immune deficiencies.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong style=\"color: rgb(79, 129, 189);\">\u003Cspan style=\"font-size: 15px; color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Why is a full assessment needed before HSCT?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">HSCT is a complex treatment, and it is not always best to proceed immediately after diagnosis. Before transplant, patients usually have bone marrow tests, immunophenotyping, chromosome and gene tests, measurable residual disease testing, heart and lung assessments, and infection screening.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">These tests help the team decide whether the patient can safely undergo transplant, which type of transplant and donor source may be most suitable, and when the transplant should take place. For some blood cancers, better disease control before transplant may improve the chance of a good outcome.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong style=\"color: rgb(79, 129, 189);\">\u003Cspan style=\"font-size: 15px; color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Summary\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">HSCT is an important treatment that can rebuild the blood-forming and immune systems. It is not simply a “bone marrow replacement.” The decision requires careful assessment of the disease, risk level, genetic findings, treatment response, and the patient’s overall health. For selected patients with blood cancers, bone marrow failure, inherited disorders, or immune diseases, HSCT may offer long-term remission and, in some cases, a chance of cure.\u003C\u002Fspan>\u003C\u002Fp>",[75,78,81,84],{"question":76,"answer":77},"Q1: Does HSCT mean replacing my bone marrow with someone else’s bone marrow?","No. HSCT gives healthy blood-forming stem cells through a vein. The cells then engraft in the bone marrow and help build a new blood-forming system.",{"question":79,"answer":80},"Q2: Does every person with leukemia need HSCT?","No. Treatment depends on the type and risk of leukemia, genetic findings, and response to treatment. Some patients do well with chemotherapy, targeted therapy, or immunotherapy, while some people with high-risk, relapsed, or treatment-resistant disease may need HSCT.",{"question":82,"answer":83},"Q3: Does HSCT guarantee that the disease will never return?","No. HSCT may provide long-term remission or a chance of cure, but the risk of relapse depends on the disease, disease status, transplant type, and individual factors. Long-term follow-up and monitoring remain important.",{"question":85,"answer":86},"Q4: Can an older adult have HSCT?","Age is not the only factor. Some older adults may be able to undergo HSCT after assessment of their overall health, organ function, disease risk, and the possible benefits and risks of transplant.","Hematopoietic stem cell transplantation is a treatment that helps patients rebuild normal hematopoiesis and immune function by infusing healthy hematopoietic stem cells.","2026-09-19",{"key":90,"title":91,"html":92,"relatedQuestions":93,"hotSummary":106,"updatedAt":88},"hematopoietic-stem-cell-transplantation-diseases-and-indications","Which Diseases Can HSCT Treat, and Who May Need a Transplant?","\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cspan style=\"color: rgb(15, 17, 21);  background-color: rgb(255, 255, 255);\">Overview: \u003C\u002Fspan>Hematopoietic stem cell transplantation (HSCT) uses healthy blood-forming stem cells to rebuild blood production and immune function. It may be used for selected blood cancers, bone marrow failure disorders, inherited conditions, and immune deficiencies.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Whether a person needs HSCT depends on the disease, risk group, genetic test results, response to treatment, and overall health. HSCT is not the right option for everyone.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"color: rgb(79, 129, 189);\">\u003Cspan style=\"color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"color: rgb(79, 129, 189);\">\u003Cspan style=\"color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"color: rgb(79, 129, 189);\">\u003Cspan style=\"color: rgb(50, 50, 50);\">Which diseases may be treated with HSCT?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">HSCT is not used only for leukemia. It is an important treatment for several types of blood and immune disorders, including blood cancers, bone marrow failure, selected inherited diseases, and some immune system disorders. The reason for transplant and the treatment goal may differ from one disease to another.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"color: rgb(79, 129, 189);\">\u003Cspan style=\"color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"color: rgb(79, 129, 189);\">\u003Cspan style=\"color: rgb(50, 50, 50);\">Which patients with blood cancer may need HSCT?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"color: rgb(79, 129, 189);\">\u003Cspan style=\"color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Acute leukemia: HSCT may be considered for some patients with high-risk acute leukemia, relapsed leukemia, or disease that remains at high risk of returning after treatment. The goals may include reducing remaining abnormal cells, rebuilding healthy blood production, and using donor immune cells to fight leukemia. Not every patient with acute leukemia needs a transplant; some may achieve long-term remission with chemotherapy, targeted therapy, or immunotherapy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Myelodysplastic syndromes (MDS): MDS is a group of disorders caused by abnormal blood-forming stem cells. Some high-risk cases may progress to acute myeloid leukemia. For suitable patients, allogeneic HSCT is one of the treatments that may offer a chance of cure.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Lymphoma: Autologous HSCT may be used for some patients with relapsed or treatment-resistant lymphoma, or as consolidation when the disease has responded to treatment but the risk of relapse remains high. The decision depends on the type and stage of lymphoma, previous treatment, treatment response, and overall health.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Multiple myeloma: For eligible patients, autologous HSCT may be an important part of treatment. The team considers age, general health, organ function, disease control, and response to earlier treatment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px; color: rgb(79, 129, 189);\">\u003Cspan style=\"color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Which non-cancerous conditions may be treated with HSCT?\u003C\u002Fstrong>\u003Cspan style=\"font-size: 18px;\">\u003Cstrong style=\"font-size: 15px; color: rgb(79, 129, 189);\">\u003Cspan style=\"color: rgb(50, 50, 50);\">\u003C\u002Fspan>\u003C\u002Fstrong>\u003Cstrong style=\"font-size: 15px; color: rgb(79, 129, 189);\">\u003C\u002Fstrong>\u003C\u002Fspan>\u003Cspan style=\"font-size: 16px;\">\u003Cstrong style=\"font-size: 15px; color: rgb(79, 129, 189);\">\u003Cspan style=\"color: rgb(50, 50, 50);\">\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Aplastic anemia: Severe aplastic anemia occurs when the bone marrow cannot make enough red cells, white cells, and platelets. Allogeneic HSCT may be an important option for some younger, eligible patients who have a suitable donor.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Inherited blood disorders: Some inherited conditions are caused by an abnormal blood-forming system. HSCT may correct the underlying problem in selected patients, including some people with thalassemia or inherited metabolic disorders.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Immune deficiencies: Some congenital immune disorders prevent the immune system from working normally. HSCT may help rebuild immune function in selected patients.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cbr\u002F>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong>Is HSCT suitable for every patient?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">No. The transplant team assesses the disease type and risk, response to treatment, and the patient’s overall health.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Disease type and risk matter because some lower-risk conditions may respond well to medicines, while high-risk disease may require earlier consideration of transplant.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Treatment response also affects timing. The team may review whether leukemia is in complete remission, whether measurable residual disease (MRD) remains, and whether the disease burden is still high.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Before transplant, heart, lung, liver, and kidney function are checked, along with infection status and general fitness, because conditioning and the early recovery period can place significant stress on the body.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"color: rgb(79, 129, 189);\">\u003Cspan style=\"color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"color: rgb(79, 129, 189);\">\u003Cspan style=\"color: rgb(50, 50, 50);\">Why do patients with the same disease receive different plans?\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Blood diseases are highly variable. Even patients with the same diagnosis may have different genetic changes, risk levels, ages, health conditions, and responses to treatment. Modern care therefore uses risk-based and personalized treatment. The transplant team reviews the full set of test results to decide whether HSCT is likely to provide more benefit than risk.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px; color: rgb(79, 129, 189);\">\u003Cspan style=\"color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>What preparation is needed before HSCT?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Disease assessment may include bone marrow examination, immunophenotyping, chromosome tests, gene tests, and MRD testing.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">For allogeneic HSCT, donor assessment includes HLA matching, a health check for the donor, and planning the transplant approach.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">The patient also has assessments of heart, lung, liver, and kidney function, along with infection screening. These steps help reduce risk and improve safety.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px; color: rgb(79, 129, 189);\">\u003Cspan style=\"color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Summary\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">HSCT is not a fixed treatment for one disease. It is an important option for selected blood cancers and related disorders. Today, transplant decisions are increasingly based on precise diagnosis, risk assessment, and the individual needs of each patient.\u003C\u002Fspan>\u003C\u002Fp>",[94,97,100,103],{"question":95,"answer":96},"Q1: Does every person with leukemia need HSCT?","No. The decision depends on the type and risk of leukemia, genetic findings, and response to treatment. Some patients may do well with chemotherapy, targeted therapy, or immunotherapy, while others with high-risk or relapsed disease may need a transplant.",{"question":98,"answer":99},"Q2: Is HSCT always the final treatment option?","No. For some high-risk patients, transplant may be planned while the disease is well controlled rather than waiting until all other options have failed.",{"question":101,"answer":102},"Q3: Is HSCT needed after CAR T-cell therapy?","Some patients may need it. The team considers the response to CAR T-cell therapy, the risk of relapse, and the features of the disease before deciding whether a transplant should follow.",{"question":104,"answer":105},"Q4: Can I have a transplant if there is no fully matched sibling donor?","Possibly. Donor options may include a haploidentical family member, an unrelated donor, or cord blood. The transplant team will assess which source is most suitable.","Find out which blood cancers, bone marrow failure disorders, inherited conditions, and immune deficiencies may be treated with HSCT.",{"key":108,"title":109,"html":110,"relatedQuestions":111,"hotSummary":124,"updatedAt":88},"hematopoietic-stem-cell-transplantation-process","What Happens During HSCT? A Step-by-Step Guide to the Transplant Process","\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Overview: HSCT is a complex treatment, not a single stem cell infusion. The process usually includes pre-transplant assessment, donor selection and stem cell collection, conditioning, stem cell infusion, early recovery, and long-term follow-up. The exact steps and timing vary with the disease, transplant type, and the patient’s health.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px; color: rgb(79, 129, 189);\">\u003Cspan style=\"color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>What happens before transplant?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Before HSCT, the team confirms the disease status, decides whether the timing is right, and checks whether the patient can safely undergo transplant.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Disease assessment may include the diagnosis and risk group, bone marrow findings, chromosome and gene test results, measurable residual disease (MRD), and response to previous treatment. These results help the team decide whether more treatment is needed before transplant and when HSCT may provide the most benefit. In some patients with acute leukemia, better disease control before transplant may reduce the risk of relapse.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Health assessment usually includes heart and lung tests, liver and kidney function, infection screening, and a review of nutrition. These checks help identify risks and guide a safer, personalized treatment plan.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px; color: rgb(79, 129, 189);\">\u003Cspan style=\"color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>How is a donor found for allogeneic HSCT?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">For allogeneic HSCT, donor selection is based mainly on human leukocyte antigen (HLA) matching. HLA markers help determine how closely the donor’s immune system matches the patient.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Common donor sources include a fully matched brother or sister, an unrelated volunteer donor, and a haploidentical family member such as a parent, child, or partially matched relative. Advances in haploidentical transplantation mean that more patients can now find a donor option.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px; color: rgb(79, 129, 189);\">\u003Cspan style=\"color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>How are stem cells collected?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Stem cells may come from peripheral blood, bone marrow, or cord blood. Peripheral blood collection is widely used.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">For peripheral blood collection, the donor or patient first receives medicines that move more stem cells from the bone marrow into the bloodstream. Blood then passes through an apheresis machine, which separates and collects the stem cells while returning the rest of the blood. The process is similar to blood donation and usually does not require an operating room. The collected cells are tested for number and quality and are stored until needed.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px; color: rgb(79, 129, 189);\">\u003Cspan style=\"color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>What is conditioning, and why is it needed?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Conditioning is the treatment given before the stem cell infusion. Depending on the plan, it may include chemotherapy, radiation therapy, or both.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Conditioning helps reduce remaining cancer cells and makes space in the bone marrow so that the new stem cells can engraft. The intensity is chosen according to the disease, age, general health, and type of transplant.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px; color: rgb(79, 129, 189);\">\u003Cspan style=\"color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>How are the stem cells given?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">HSCT is usually not an operation. After conditioning, the stem cells are infused through a vein, much like a blood transfusion. The cells travel through the bloodstream to the bone marrow, where they may engraft and begin producing new blood cells.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px; color: rgb(79, 129, 189);\">\u003Cspan style=\"color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>What happens after the infusion?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Engraftment and blood count recovery: The new cells need time to begin working. The team closely monitors white blood cells, neutrophils, and platelets. Infection risk is high before blood counts recover, so infection prevention and supportive care are especially important.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Immune recovery: Immune recovery, especially after allogeneic HSCT, takes longer than blood count recovery. The team watches for infection, graft-versus-host disease (GVHD), and medicine-related side effects, and adjusts treatment as needed.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Long-term follow-up: Follow-up may include blood tests, MRD and gene testing, imaging when needed, and checks for transplant-related complications. Regular monitoring helps the team find and manage changes early.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px; color: rgb(79, 129, 189);\">\u003Cspan style=\"color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>How long does the entire process take?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Timing is different for every patient. Pre-transplant assessment may take several weeks. Finding and preparing a donor can vary widely. Conditioning, infusion, and early inpatient recovery usually take several weeks. Blood production may recover over weeks, while immune recovery can take months or longer. HSCT is therefore a long-term process that requires close cooperation between the patient, family, and care team.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px; color: rgb(79, 129, 189);\">\u003Cspan style=\"color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Summary\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">HSCT includes many connected steps, and each step can affect safety and outcome. Modern transplantation combines precise diagnosis, risk assessment, supportive care, disease monitoring, and long-term management rather than focusing only on the stem cell infusion itself.\u003C\u002Fspan>\u003C\u002Fp>",[112,115,118,121],{"question":113,"answer":114},"Q1: How long will I stay in the hospital?","The length of stay depends on the disease, transplant type, complications, and speed of recovery. Patients usually remain in hospital through conditioning, stem cell infusion, early blood count recovery, and observation for early complications.",{"question":116,"answer":117},"Q2: Which stage is usually the most difficult?","Challenges differ from one patient to another. The period after conditioning and before blood counts recover often carries the highest infection risk. Patients having allogeneic HSCT also need monitoring for GVHD.",{"question":119,"answer":120},"Q3: Does recovery of blood counts mean the transplant has fully succeeded?","Not by itself. Blood count recovery shows that blood production is returning, but long-term disease control must also be assessed with MRD testing, gene tests, and follow-up.",{"question":122,"answer":123},"Q4: Will I need more treatment after HSCT?","Some patients may need maintenance treatment, immune-based therapy, or treatment to reduce the risk of relapse. The plan depends on the disease and transplant course.","Understand the HSCT process, from pre-transplant tests and donor selection to conditioning, stem cell infusion, recovery, and follow-up.",{"key":126,"title":127,"html":128,"relatedQuestions":129,"hotSummary":142,"updatedAt":88},"autologous-and-allogeneic-stem-cell-transplantation","What Are the Types of HSCT? Autologous vs Allogeneic Transplant","\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Overview: The two main types of hematopoietic stem cell transplantation are autologous HSCT and allogeneic HSCT. Autologous HSCT uses the patient’s own stem cells. Allogeneic HSCT uses stem cells from a healthy donor.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Autologous HSCT is commonly used for some lymphomas and multiple myeloma. Allogeneic HSCT can rebuild blood production and may also allow donor immune cells to attack cancer. It is often considered for selected high-risk blood cancers. The best approach depends on the disease, risk level, treatment goals, and the patient’s health.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong style=\"color: rgb(79, 129, 189);\">\u003Cspan style=\"font-size: 15px; color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong style=\"color: rgb(79, 129, 189);\">\u003Cspan style=\"font-size: 15px; color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>What is autologous HSCT?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">In autologous HSCT, the patient’s own stem cells are collected and stored before intensive treatment. After high-dose treatment, the stored cells are infused back into the patient to help blood production recover.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">The usual steps are stem cell mobilization, collection through an apheresis machine, freezing and storage, high-dose treatment, and reinfusion of the stored cells.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cbr\u002F>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Which diseases may be treated with autologous HSCT?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Lymphoma: Autologous HSCT may be used for some patients with a high risk of relapse, for relapsed disease, or as consolidation after a good response to treatment. The decision depends on lymphoma type and stage, previous treatment, response, and overall health.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Multiple myeloma: Autologous HSCT is an important part of treatment for some eligible patients. The team assesses age, health, organ function, and disease control.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Other blood diseases: In selected situations, autologous HSCT may also be considered for other conditions.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong style=\"color: rgb(79, 129, 189);\">\u003Cspan style=\"font-size: 15px; color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>What is allogeneic HSCT?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Allogeneic HSCT uses stem cells from a healthy donor to replace or rebuild the patient’s abnormal blood-forming and immune systems. The donor may be a matched sibling, an unrelated volunteer, a haploidentical family member, or a cord blood unit.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong style=\"color: rgb(79, 129, 189);\">\u003Cspan style=\"font-size: 15px; color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>How can allogeneic HSCT treat blood cancer?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">In addition to restoring blood production, donor immune cells may recognize and attack cancer cells that remain after treatment. This is called the graft-versus-leukemia (GVL) effect or, more broadly, the graft-versus-tumor (GVT) effect. This immune effect is an important reason that allogeneic HSCT may help some patients with high-risk leukemia and other blood cancers.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong style=\"color: rgb(79, 129, 189);\">\u003Cspan style=\"font-size: 15px; color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Who may need allogeneic HSCT?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Allogeneic HSCT may be considered for selected patients with high-risk acute myeloid leukemia (AML), high-risk acute lymphoblastic leukemia (ALL), relapsed or treatment-resistant leukemia, high-risk myelodysplastic syndromes (MDS), severe aplastic anemia, and some inherited blood disorders.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong style=\"color: rgb(79, 129, 189);\">\u003Cspan style=\"font-size: 15px; color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>How do autologous and allogeneic HSCT differ?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Autologous HSCT uses the patient’s own cells and does not require a donor. It usually does not provide a donor immune effect and has a lower risk of donor-related immune complications. Common uses include selected lymphomas and multiple myeloma.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Allogeneic HSCT uses cells from a healthy donor and requires donor matching. It may provide a graft-versus-tumor effect, but it also carries risks such as graft-versus-host disease (GVHD). It is often used for leukemia, high-risk MDS, and selected other conditions.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong style=\"color: rgb(79, 129, 189);\">\u003Cspan style=\"font-size: 15px; color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Where can the stem cells come from?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Peripheral blood: Widely used. Collection is well established, and blood count recovery may be relatively fast.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Bone marrow: A traditional source collected directly from the bone marrow.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Cord blood: Collected from a newborn’s umbilical cord and placenta. It can be used as a stem cell source for selected patients.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong style=\"color: rgb(79, 129, 189);\">\u003Cspan style=\"font-size: 15px; color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>How is the transplant type chosen?\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Neither type is simply “better” or “safer” for every patient. The choice depends on the disease, treatment goal, risk of relapse, age, general health, and expected transplant risks. Autologous HSCT may be more suitable for some patients with lymphoma or multiple myeloma, while allogeneic HSCT may offer more benefit for some high-risk leukemias. The transplant team makes an individualized recommendation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"font-size: 15px;\">\u003Cstrong style=\"color: rgb(79, 129, 189);\">\u003Cspan style=\"font-size: 15px; color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"font-size: 16px;\">\u003Cstrong>Summary\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin: 2px 0px 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Autologous HSCT uses the patient’s own stem cells and is often used for selected lymphomas and multiple myeloma. Allogeneic HSCT uses donor cells, can rebuild blood and immune function, and may provide an immune effect against cancer. The right choice depends on the disease and the individual patient.\u003C\u002Fspan>\u003C\u002Fp>",[130,133,136,139],{"question":131,"answer":132},"Q1: Is autologous HSCT lower risk?","It does not cause donor-related immune complications such as GVHD, so some risks are lower. However, infection, side effects from high-dose treatment, and disease relapse can still occur.",{"question":134,"answer":135},"Q2: Is allogeneic HSCT always more effective?","No. It can provide a donor immune effect against cancer, but it also carries additional risks. The best option depends on the disease and the patient’s condition.",{"question":137,"answer":138},"Q3: Can I have allogeneic HSCT without a brother or sister donor?","Yes, in many cases. Other options include a haploidentical family donor, an unrelated donor, or cord blood.",{"question":140,"answer":141},"Q4: How are CAR T-cell therapy and HSCT related?","Both are important treatments for blood cancers. Some patients may have CAR T-cell therapy first and then be assessed for HSCT based on treatment response and the risk of relapse. One does not simply replace the other.","Compare autologous and allogeneic HSCT, including stem cell source, common uses, benefits, donor needs, and immune-related risks.",{"key":144,"title":145,"html":146,"relatedQuestions":147,"hotSummary":160,"updatedAt":88},"age-limit-for-hematopoietic-stem-cell-transplantation","Is There an Age Limit for HSCT? Can Older Adults Have a Transplant?","\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">There is no single absolute age limit for HSCT. The decision is not based on age alone. The transplant team looks at overall health, organ function, the type and risk of the disease, and the possible benefits and risks of transplant.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Advances in conditioning, supportive care, and transplant techniques mean that some older adults may be able to undergo HSCT with a treatment plan adjusted to their needs.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px; color: rgb(79, 129, 189);\">\u003Cspan style=\"color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px; color: rgb(79, 129, 189);\">\u003Cspan style=\"color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Why is age not the only factor?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">In the past, older adults had fewer transplant options because conditioning was often intensive and the risks of infection and other complications were high. Today, the key questions are whether the patient is likely to benefit and whether the body can tolerate the process.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">The team considers “biological age,” not only the number of years a person has lived. An older adult who is active, has few other health problems, and has good heart and lung function may be a better candidate than a younger person with serious medical conditions.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px; color: rgb(79, 129, 189);\">\u003Cspan style=\"color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>What does the medical assessment include?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Overall health and daily function: The team reviews mobility, independence, other illnesses, and the ability to manage treatment and recovery.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Organ function: Heart, lung, liver, and kidney tests help show whether the body can process medicines and tolerate transplant.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Infection status: Active infections or a high infection risk may need to be managed before transplant.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Disease and treatment need: Some older patients with high-risk acute leukemia may still benefit from transplant, while patients with lower-risk disease may have effective non-transplant options. The decision balances disease risk, current response, and expected benefit.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px; color: rgb(79, 129, 189);\">\u003Cspan style=\"color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>What challenges may older adults face?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Older adults may recover more slowly, have lower organ reserve, and tolerate side effects less well. They are also more likely to have other medical conditions and may face a higher risk of infection. Careful infection prevention, nutrition support, rehabilitation, and early monitoring are therefore especially important.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px; color: rgb(79, 129, 189);\">\u003Cspan style=\"color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>How may the transplant plan be adjusted?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Reduced-intensity conditioning (RIC): RIC uses a less intensive conditioning approach than traditional myeloablative regimens. It may reduce treatment-related toxicity and make transplant possible for some older or less fit patients.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Individualized treatment: The team may adjust conditioning intensity, immune-suppressing medicines, donor selection, and post-transplant care according to the patient’s health, disease risk, and support needs.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px; color: rgb(79, 129, 189);\">\u003Cspan style=\"color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>What additional assessment may be useful for older adults?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">A geriatric assessment may review daily activities, nutrition, memory and thinking, emotional health, and social support.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">The transplant team also estimates the risk of treatment-related death, the risk of relapse, and the chance of long-term benefit. The goal is not only to treat the disease but also to protect quality of life as much as possible.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px; color: rgb(79, 129, 189);\">\u003Cspan style=\"color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Can older adults benefit from HSCT?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Some carefully selected older adults can benefit from HSCT and achieve meaningful disease control. Outcomes depend on many factors, including disease type, disease status, organ function, transplant approach, and supportive care. Age alone cannot predict whether transplant will be successful.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px; color: rgb(79, 129, 189);\">\u003Cspan style=\"color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Summary\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">HSCT has no fixed age cutoff that applies to every person. Overall health, organ function, disease features, transplant risk, and expected benefit are more important than age alone. Every patient needs an individual assessment by an experienced transplant team.\u003C\u002Fspan>\u003C\u002Fp>",[148,151,154,157],{"question":149,"answer":150},"Q1: Can someone over 70 have HSCT?","Some people can. The team will assess overall health, organ function, disease risk, and the expected benefits and risks. Age over 70 is not automatically an absolute barrier.",{"question":152,"answer":153},"Q2: Do younger patients always have better results?","No. Younger age may be linked to faster recovery, but outcome also depends on disease type, disease control, genetic risk, transplant plan, and many other factors.",{"question":155,"answer":156},"Q3: Are older adults limited to conservative treatment?","No. Depending on the disease and health status, options may include targeted therapy, immunotherapy, HSCT, or a combination of treatments.",{"question":158,"answer":159},"Q4: What are the main transplant risks for older adults?","A: Important risks include infection, organ injury, GVHD after allogeneic HSCT, and disease relapse. Careful assessment and structured post-transplant care can help reduce these risks.","Age alone does not decide whether someone can have HSCT. Learn how health, organ function, disease risk, and transplant benefit are assessed.",{"key":162,"title":163,"html":164,"relatedQuestions":165,"hotSummary":178,"updatedAt":88},"second-hematopoietic-stem-cell-transplantation","What Is a Second HSCT, and Who May Need Another Transplant?","\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Overview: A second hematopoietic stem cell transplant, or second HSCT, means having another stem cell transplant after a previous transplant. It may be considered if the disease returns, the first transplant does not control the disease as expected, the graft fails to engraft, or graft function becomes poor.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Not every patient with a problem after transplant needs a second HSCT. The decision depends on the disease, the reason for considering another transplant, the patient’s health, the results of the first transplant, and the possible benefits and risks.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px; color: rgb(79, 129, 189);\">\u003Cspan style=\"color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px; color: rgb(79, 129, 189);\">\u003Cspan style=\"color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Why might a second HSCT be considered?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Relapse after transplant: This is one of the most common reasons. Signs may include increasing leukemia cells, new bone marrow abnormalities, measurable residual disease (MRD) becoming positive again, or other test results showing progression. If the disease can be brought back under control and the patient is fit enough, a second HSCT may be considered.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Poor disease control after the first transplant: Some patients may not reach complete remission or may have persistent disease. Other treatments, such as medicines, targeted therapy, or immunotherapy, may be used first. A second HSCT may then be considered in selected cases.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Graft failure or poor graft function: In rare cases, donor cells may not engraft, may not produce enough blood cells, or may stop working well. The team will investigate the cause and decide whether another transplant is appropriate.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px; color: rgb(79, 129, 189);\">\u003Cspan style=\"color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Who may be suitable for a second transplant?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Disease control: A key question is whether the disease can be brought into remission or reduced to a lower burden before the second transplant. In many cases, better disease control before transplant is linked to a greater chance of benefit.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Ability to tolerate treatment: The patient must be reassessed for heart and lung function, liver and kidney function, infection, nutrition, and overall fitness because a second transplant involves another conditioning regimen, immune suppression, and recovery period.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Experience after the first transplant: The team reviews the type of first transplant, how long remission lasted, whether severe graft-versus-host disease occurred, how well the graft worked, and what complications developed. These details affect the second transplant plan.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px; color: rgb(79, 129, 189);\">\u003Cspan style=\"color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>How is a second HSCT different from the first?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Patients considering a second HSCT have already had chemotherapy, transplant, immune-suppressing treatment, and possibly infections or other complications. Their organ reserve and recovery ability may therefore be different.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">The disease may also be more complex or resistant. The conditioning regimen, donor choice, immune strategy, and follow-up plan often need further individual adjustment.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px; color: rgb(79, 129, 189);\">\u003Cspan style=\"color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>What tests are needed before a second HSCT?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Disease assessment may include bone marrow examination, flow cytometry, gene testing, and MRD testing.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">Health assessment includes heart and lung tests, liver and kidney function, infection screening, and nutritional evaluation.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">For a second allogeneic HSCT, the team also considers whether to use the original donor or a different donor and reviews HLA matching and the overall transplant strategy.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cstrong style=\"font-size: 15px; color: rgb(79, 129, 189);\">\u003Cspan style=\"color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>What other treatments may be considered after relapse?\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">A second HSCT is not the only option after relapse. Depending on the disease and earlier treatments, options may include targeted therapy, immunotherapy, CAR T-cell therapy, a clinical trial, or supportive care. Some treatments may help bring the disease back under control before the team decides whether another transplant is needed.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cstrong style=\"font-size: 15px; color: rgb(79, 129, 189);\">\u003Cspan style=\"color: rgb(50, 50, 50);\">\u003Cbr\u002F>\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Summary\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cbr\u002F>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp style=\"margin-bottom: 7px;\">\u003Cspan style=\"color: rgb(40, 40, 40); font-size: 15px;\">A second HSCT may be considered for selected patients after relapse, poor disease control, graft failure, or poor graft function. The decision requires careful review of disease status, overall health, the first transplant, and the expected benefit of another transplant. New targeted therapies, immune treatments, CAR T-cell therapy, and improved transplant care give some patients additional treatment choices.\u003C\u002Fspan>\u003C\u002Fp>",[166,169,172,175],{"question":167,"answer":168},"Q1: Does failure of the first transplant always mean I need a second HSCT?","No. The team first identifies why the first transplant did not work as expected and reviews the current disease and health status. Other treatments may be more suitable for some patients.",{"question":170,"answer":171},"Q2: Is the chance of success always lower with a second HSCT?","A second transplant can be more challenging, but outcome depends on the disease, the time to relapse, disease control before the second transplant, overall health, and the transplant plan. It cannot be predicted from the transplant number alone.",{"question":173,"answer":174},"Q3: How soon after the first transplant might a second transplant be needed?","Timing varies. Some patients relapse soon after transplant, while others relapse years later. The team considers the timing and disease features when planning treatment.",{"question":176,"answer":177},"Q4: Is a new donor always needed?","No. For an allogeneic second transplant, the team may use the same donor or choose a different donor. The decision depends on the reason for the second transplant and the planned immune strategy.","Learn why a second HSCT may be considered after relapse, graft failure, or poor response, and how patients are assessed for another transplant. ",[],{"author":68,"reviewedBy":68,"lastReviewed":181,"datePublished":181,"citations":182,"disclaimer":68},"2023-12-01",[],false,1792294305938]